Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial

SK Thomas, LW Kwak - Seminars in oncology, 2012 - Elsevier
Many of the efforts toward developing vaccines against human malignancies have been
frustrated by the lack of identification of a tumor-specific antigen that would allow tumor cells
to be distinguished from normal cells. Idiotypic determinants of the surface immunoglobulin
(Ig) associated with a given patient's B-cell lymphoma are unique to that tumor, and can thus
serve as a tumor-specific marker. When conjugated to the immune carrier keyhole limpet
hemocyanin (KLH), vaccination with an idiotype protein vaccine has been able to improve …